Novo Nordisk A/S has published its latest weekly update on its ongoing share repurchase programme, disclosing the buyback of 1,440,000 B shares between 26 October and 2 November 2026. The transactions bring the total accumulated repurchases under the current sub-programme to 26,955,000 B shares at a combined value of DKK 7,764,364,812. The update forms part of Novo Nordisk's broader DKK 15 billion buyback initiative running over a 12-month period from 4 February 2026, conducted under EU Market Abuse Regulation safe harbour rules.

Key Points

  • Novo Nordisk A/S Class B (0QIU), listed on Nasdaq Copenhagen as Novo-B and on the New York Stock Exchange as NVO
  • Novo Nordisk repurchased 240,000 B shares on each of six trading days between 26 October and 2 November 2026
  • Accumulated repurchases since 4 February 2026 total 41,714,179 B shares at an average price of DKK 277.23, equating to DKK 11,564,364,801
  • Investors will be watching whether the company reaches its DKK 15 billion programme ceiling before the 4 February 2027 deadline

Weekly Transaction Detail: 240,000 B Shares Bought Daily at Prices Ranging from DKK 257.51 to DKK 267.29

Over the six trading sessions covered by the announcement, Novo Nordisk purchased exactly 240,000 B shares each day. Average purchase prices ranged from a low of DKK 257.51 on 28 October to a high of DKK 267.29 on 2 November 2026, generating daily transaction values between DKK 61,801,617 and DKK 64,148,584. The six sessions collectively added approximately DKK 377,016,700 in repurchased stock to the programme's running total, pushing accumulated spend under the sub-programme initiated on 6 May 2026 to DKK 7,764,364,812 against a sub-programme ceiling of DKK 11,200,000,010.45.

Novo Nordisk Now Holds 55,754,876 Treasury B Shares, Equal to 1.2% of Total Share Capital

Following the transactions reported in this update, the Danish pharmaceutical company holds 55,754,876 B shares as treasury stock, representing 1.2% of total share capital. The company's combined A and B share count stands at 4,465,000,000 shares including treasury holdings. Each B share carries a nominal value of DKK 0.10. Treasury shares acquired under buyback programmes are commonly used for employee incentive schemes or subsequently cancelled to reduce share count, though the announcement does not specify Novo Nordisk's intended use for these particular shares.

Overall DKK 15 Billion Programme at DKK 11.56 Billion Spent Since February 2026

Since the overarching DKK 15 billion repurchase programme commenced on 4 February 2026, Novo Nordisk has spent DKK 11,564,364,801 buying back 41,714,179 B shares at an average price of DKK 277.23. The programme is structured to conclude within a 12-month window ending 4 February 2027 and operates in compliance with Article 5 of EU Regulation No 596/2014 and the Commission Delegated Regulation (EU) 2016/1052. Novo Nordisk is a global healthcare company employing over 67,000 people worldwide, focused on developing treatments across therapeutic areas including diabetes and obesity.